Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 3/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 8/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.33 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29468876 | 0.89 | CTSD (0.41) | ABCB1MMP1 | |
| SCHEMBL30250305 | 0.86 | CTSD (0.44) | REN | |
| SCHEMBL30422766 | 0.85 | CTSD (0.42) | ABCB1MMP1REN | |
| SCHEMBL30250381 | 0.83 | CTSD (0.42) | RENCTSLCTSK | |
| SCHEMBL30250304 | 0.82 | FNTA (0.39) | CTSK | |
| SCHEMBL26578688 | 0.82 | GRN (0.36) | — | |
| SCHEMBL30541988 | 0.80 | CASP3 (0.43) | REN | |
| SCHEMBL31518742 | 0.80 | PSEN1 (0.42) | RENCTSK | |
| SCHEMBL29468879 | 0.79 | ABCB1 (0.41) | ABCB1MMP1 | |
| SCHEMBL31094178 | 0.79 | CTSL (0.46) | ABCB1MMP1RENACACBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364194-A1 | GLP-1R/GCGR Dual Target Agonist Polypeptide Derivative for Treatment of Hepatic Fibrosis Associated with Viral Hepatitis | SHENZHEN TURIER BIOTECH CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364194-A1 | GLP-1R/GCGR Dual Target Agonist Polypeptide Derivative for Treatment of Hepatic Fibrosis Associated with Viral Hepatitis | GLP1R, GCGR, GIPR | ABCB1 1633/4885MMP1 604/4885ITGB3 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.